Open label randomized clinical trial of standard neoadjuvant chemotherapy (paclitaxel followed by FEC) versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer.

Trial Profile

Open label randomized clinical trial of standard neoadjuvant chemotherapy (paclitaxel followed by FEC) versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Everolimus (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2016 Planned End Date changed from 1 Apr 2015 to 1 Apr 2017.
    • 15 Dec 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top